xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

Al's Comment:

 This compassionate use program is for Glioblastoma (and any other cancer)  patients who have mutations in the MAPK pathway  including  these mutations: KRAS, NRAS, HRAS, BRAF, MEK, and ERK,  Take a look at your pathoilogy report and see if any of those mutations are present. If they are, ask your doctor about this program.

Disclaimer:  I own stock in xCures and work as a paid consultant for them.


Posted on: 09/28/2020

xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

 


Click HERE to return to brain tumor news headlines.